Relebactam

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Relebactam
Relebactam structure.svg
Clinical data
SynonymsMK-7655
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC12H20N4O6S
Molar mass348.37 g·mol−1
3D model (JSmol)

Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor,[1] it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio).[2]

See also[edit]

References[edit]

  1. ^ Papp-Wallace, Krisztina M.; Barnes, Melissa D.; Alsop, Jim; Taracila, Magdalena A.; Bethel, Christopher R.; Becka, Scott A.; Van Duin, David; Kreiswirth, Barry N.; Kaye, Keith S.; Bonomo, Robert A. (2018). "Relebactam is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae". Antimicrobial Agents and Chemotherapy. 62 (6). doi:10.1128/AAC.00174-18. PMC 5971601. PMID 29610205.
  2. ^ "FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections". Food and Drug Administration. July 17, 2019.